Article Test

Home  >  Medical Research Archives  >  Issue 149  > Current insight on irinotecan dose adjustment in advanced colorectal cancers based on pharmacogenetic studies: an updated review
Published in the Medical Research Archives
May 2024 Issue

Current insight on irinotecan dose adjustment in advanced colorectal cancers based on pharmacogenetic studies: an updated review

Published on May 26, 2024

DOI 

Abstract

 

Despite advancements in colorectal cancer screening and treatment, the occurrence, severity, and mortality rates have consistently risen among younger patients. Precision medicine aims to personalize cytotoxic drug dosages, such as irinotecan, by considering the pharmacogenetic specificity of glucuronidation backgrounds. Our search, focused on recent developments (2020-2024) in categorizing Uridine 5'-diphosphate-glucuronosyltransferase (UGT)1A1 variants related to irinotecan's safety, effectiveness, and cost-benefit in metastatic colorectal cancer patients identified 32 relevant clinical studies and recent reviews from 296 abstracts in PubMed and PubMed Central databases. This updated review emphasizes racial disparities in the incidence and essential variants influencing irinotecan's activated metabolite (SN-38). While UGT1A1*28 homozygosity is the primary cause of toxicity in North America, Europe, and a Middle Asian country, UGT1A1*6 is the prominent variant responsible in East Asian countries. Despite various methods employed for dose adjustment based on pharmacogenomic findings, individualization of the dose has been associated with reduced toxicity, improved response, and enhanced patient survival. The recommended irinotecan dose in the FOLFIRI regimen can be variable between 120mg/m2 to 350 mg/m2 based on the UGT1A1 genotype variant. Moreover, this approach appears to be cost-effective, as suggested by European and Chinese studies.

Author info

Sanambar Sadighi, Pouyan Shaker, Mohammad Shafiee

Have an article to submit?

Submission Guidelines

Submit a manuscript

Become a member

Call for papers

Have a manuscript to publish in the society's journal?